For endemic systemic fungal infections
TOLSURA offers an evolution in antifungal treatment
Improved bioavailability compared to conventional itraconazole capsules1
Studies have shown that TOLSURA 65 mg capsules offer nearly twice the bioavailability of conventional itraconazole 100 mg capsules*
81% of subjects treated with TOLSURA achieved a Ctrough mean level of >1000 ng/mL compared to 44% taking conventional itraconazole capsules
*Although the active substance, pharmaceutical form, and route of administration are the same, due to the increased drug absorption seen with TOLSURA 65 mg capsules, it should not be used interchangeably with other formulations of itraconazole.
Learn more about the bioavailability of TOLSURAThe efficacy of itraconazole with SUBA™ technology for predictable absorption1
SUBA™ technology allows for significantly improved absorption in the higher pH of the upper small intestine
This helps improve bioavailability, delivering consistent levels of medicine throughout treatment
the bioavailability of conventional itraconazole capsules1,2
Find out more about SUBA™ technologyTOLSURA is available in a smaller, 65 mg capsule compared to conventional itraconazole capsules1
TOLSURA 65 mg capsules must be taken with food, so patients can incorporate the dosing into their meal schedule2
May be taken while patients are using acid-reducing medications such as PPIs under the direction of their healthcare provider2*
*Co-administration of PPIs, including omeprazole, with TOLSURA increases the systemic exposure to itraconazole. Monitor for adverse reactions.
Learn more about TOLSURA dosing